<DOC>
	<DOCNO>NCT00832728</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , concurrent control study subject FHF . Subjects meet eligibility requirement study randomly assign 2:1 ratio receive either standard medical therapy FHF plus ELAD® system , standard medical therapy alone , latter defined conventional therapy FHF determine clinically appropriate treat physician .</brief_summary>
	<brief_title>Safety Efficacy Extracorporeal Liver Assist Device ( ELAD® ) In Patients With Fulminant Hepatic Failure ( FHF )</brief_title>
	<detailed_description>Therapy generally include treatment hepatic encephalopathy use lactulose without oral antibiotic , antibiotic indicate treat infection , volume resuscitation vasopressor indicate treat hypotension . In addition general medical treatment glucose control renal replacement therapy use necessary . Subjects clinical diagnosis hepato-renal syndrome may treat midodrine octreotide terlipressin , consider appropriate therapy . Immediately prior treatment initiation , subject eligibility confirm . Treatment ELAD® continue minimum 3 day maximum 30 day , , Investigator 's opinion , clinical status improve relative entry ; subject undergoes OLT ; continue use ELAD® contraindicate , describe Section 5.5 . Subjects follow discontinuation 30 day elapse since study enrollment ( control ) 30 day elapse since cessation ELAD® therapy ( ELAD® group ) , whichever come first .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>1 . Weight ≥15 kilograms ; 2 . Age ≥10 ≤65 year ; 3 . Diagnosis FHF ; 4 . Patients must treat standard regimen Nacetyl cysteine ( NAC ) involve load dose 150mg/kg/hr 1 hour follow 12.5 mg/kg/hour x 4 hour continuous infusion 6.25 mg/kg remain 67 hr . 5 . Subject designated representative must willing sign Informed Consent Form specific study comply study requirement AND EITHER 6 . Known acetaminophen ingestion diagnostic serum level , least one following : a. prothrombin time ( PT ) &gt; 30 second ( International Normalized Ratio ( INR ) &gt; 6.5 , OR ; b. Encephalopathy Grade II , III IV least one following : i. Arterial pH &lt; 7.30 ≥2 hour initial diagnosis , OR ; ii . renal failure document urine output le 2 mL/kg/hr 12 hour , OR ; iii . creatinine &gt; 2.5 mg/dL ; OR 7 . Patients NonAcetaminophenInduced FHF : . Stage II , III IV encephalopathy , presence least two follow five criterion : i. NonA/NonB hepatitis drug ( nonacetaminophen ) induce FHF ; ii . Serum bilirubin &gt; 17 mg/dL ; iii . Patient ≥10 &lt; 40 year old ; iv . Prothrombin time &gt; 25 second ( INR &gt; 3.5 ) , AND/OR ; v. Jaundice encephalopathy time ≥7 day ; OR 8 . Liver transplantation within 10 day screen procedure , meet inclusion criterion due primary graft nonfunction , receive ELAD® therapy prior first graft 1 . Cerebral Perfusion Pressure measure intracranial pressure ( ICP ) monitor . ( NOTE : In case ICP monitor placement perform prior study enrollment , exclusion criterion apply ) : 1 . Patients &gt; 18 yrs age Cerebral Perfusion Pressures ( CPP ) ≤40 mm Hg one hour longer . 2 . Patients ≤18 yrs CPP ≤35 mm Hg one hour longer . 2 . Chronic liver disease ; 3 . Concomitant disease include chronic congestive heart failure , vascular disease , emphysema , AIDS , cancer , acute fattyliver disease , hepatitis due herpes virus , Wilson 's disease , BuddChiari syndrome ; 4 . Portal hypertension ( e.g. , variceal bleed , caput Medusae , clinically obvious ascites ) ; 5 . Liver dysfunction due trauma ; 6 . Hemorrhage irreversible brain death ( i.e . blood flow study positive herniation and/or pupillary reflex absent ) ; 7 . Platelet count &lt; 50,000/mm3 reduce &lt; 80,000/mm3 72 hr . period . ( NOTE : Patient may include physician 's discretion platelet count exceed 50,000mm3 time initiation therapy manage administration blood product ) ; 8 . Mean Arterial Pressures ( MAP ) ≤50 mm Hg one hour longer measure indwell arterial line , OR ; patient ≤18 year old whose MAP ≤40 mm Hg one hour longer ; 9 . Vasopressor support exceed 1.0 µg/kg/min alphaadrenergic agent one hour longer ; 10 . Clinical radiographic evidence stroke intracerebral bleeding ; 11 . Seizures uncontrolled medication ; 12 . Acute myocardial infarction base clinical and/or electrocardiographic evidence ; 13 . Lung disease define PaO2 ≤ 60mm Hg FiO2 ≥0.6 , correct medical management ( include CVVH indicate ) ; 14 . Pregnancy determine βhCG result ; 15 . ≤2 week postpartum ; 16 . Participation another investigational study within 30 day enrollment ; 17 . Prior ELAD® therapy .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>